Physician profile
Patrick Tate
NPI 1932662970
$33,122.19
in general payments reported to CMS, 2019-2025
10 companies · $6,331 in 2025
The $6,331 reported for 2025 was more than what 84% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $27K · 2025: $6,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $27K · Travel and Lodging: $3,944 · Food and Beverage: $1,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $27,250.00 |
| Travel and Lodging | $3,943.67 |
| Food and Beverage | $1,928.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $12,500.00 | 2024 | |
| Arthrex, INC. | $10,689.44 | 2024-2025 | |
| Smith+Nephew, INC. | $4,159.95 | 2024-2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Zimmer Biomet Holdings, INC. | $3,956.83 | 2024-2025 | Comprehensive Shoulder System, Juggerknotless Soft Anchor, Persona |
| Stryker Corporation | $1,057.75 | 2024-2025 | Blueprint Patient Specific Instrumentation, Aequalis Ascend Flex, Augment Injectable |
| Tigon Medical LLC | $442.00 | 2025 | |
| Shoulder Innovations, INC. | $259.55 | 2025 | Inset System |
| Vertex Pharmaceuticals Incorporated | $19.70 | 2025 | |
| Polaris Technology Solutions LLC | $18.91 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $18.06 | 2025 | Iovera, Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.